Sarda Proteins Limited: Revised Financials and Significant Capital Raise

Sarda Proteins Limited has submitted revised audited financial results for the quarter and year ended March 31, 2026. These revisions are primarily clerical, related to interest income booking and reclassification of share warrants, with management stating no material impact on the company's financial position.

Reader Takeaway: Revised filing confirms immaterial accounting changes; capital raise bolsters balance sheet, but revenue declines.

What just happened

The company has updated its Board Meeting outcome and financial results from April 30, 2026. The revisions are described as clerical, affecting interest income and share warrant classification. Sarda Proteins also reported a substantial capital raise of ₹83.15 crore during FY2026.

Why this matters

Investors can expect a clearer picture of the company's financial standing post-revision. The significant capital infusion is crucial, as it strengthens the company's balance sheet, increasing total assets and equity substantially. However, a notable decrease in revenue from operations needs attention.

The backstory

For the financial year ended March 31, 2026, Sarda Proteins' revenue from operations stood at ₹16.16 crore, a decrease from ₹24.19 crore in FY2025. Despite this, the total profit for the period improved to ₹0.45 crore from ₹0.005 crore in the previous year. The company raised ₹83.15 crore through the issuance of share capital and securities premium, significantly impacting its financial structure.

What changes now

The company's total assets have surged to ₹86.66 crore as of March 31, 2026, from ₹2.65 crore a year prior. Total equity also saw a substantial rise to ₹86.21 crore from ₹2.38 crore. Cash and cash equivalents increased to ₹7.52 crore, reflecting the successful capital raise.

Risks to watch

Sarda Proteins operates solely within the "Renewable Energy Sector Solar Module Products" segment. This single-segment focus presents a high concentration risk, making the company's performance entirely dependent on this one business area.

Peer comparison

Information on direct peers for Sarda Proteins' specific operations in solar module products and their recent financial performance is not provided in the filing.

Context metrics (time-bound)

• Revenue from operations: ₹16.16 crore (FY2026) vs ₹24.19 crore (FY2025) - a decrease of 33.21%.
• Total Profit for the Period: ₹0.45 crore (FY2026) vs ₹0.005 crore (FY2025) - an improvement.
• Capital raised via share issuance: ₹83.15 crore (FY2026).
• Total Assets: ₹86.66 crore (March 31, 2026) vs ₹2.65 crore (March 31, 2025).
• Total Equity: ₹86.21 crore (March 31, 2026) vs ₹2.38 crore (March 31, 2025).
• Cash and cash equivalents: ₹7.52 crore (March 31, 2026).

What to track next

Investors should monitor the company's revenue growth trajectory and profitability in the renewable energy sector. The sustainability of operations given the negative net cash flow from operating activities and the effective utilization of the recently raised capital will be key factors.